Department of Microbial Biotechnology, Rajiv Gandhi Institute of IT and Biotechnology, Bharati Vidyapeeth (Deemed to be) University, Katraj, Pune, 411046, India.
BMC Complement Altern Med. 2019 Mar 19;19(1):70. doi: 10.1186/s12906-019-2470-3.
Multi-drug resistance in microorganisms is a serious problem at national as well as at a global level. Many researches have suggested alternatives to antibiotics with minimal or no major side effects. LAB is one of the most human-friendly probiotic strains known to mankind from times immemorial. With the objective to deal with progressing antibiotic resistance among microorganisms, the present work demonstrates the inhibitory activity of LAB consortium against MDR clinical isolates.
Total of nine hospital isolates of staphylococci were obtained and distinguished as S.aureus and coagulase-negative Staphylococcus (CoNS) based on their ability to ferment mannitol and form clumping with citrated plasma. All the test organisms were tested for antibiotic sensitivity with HiMedia (India) Octadisc Combi 92. Sets of L .plantarum, L .acidophilus and L.casei var. rhamnosus were prepared and tested against a standard culture of S.aureus NCIM 2129 by agar well diffusion method. To identify the primary source of substances responsible for inhibitory action, whole broth, cell-free supernatant, and cell lysate was prepared from the above-mentioned set. These were tested for their inhibitory action initially against standard S.aureus NCIM 2127, followed by clinical isolates.
The antibiotic sensitivity profile revealed that all clinical isolates were multi-drug resistant. The maximum inhibitory potential was seen in a combination of the three LAB in the ratio 1:1:1. Highest antagonistic activity was observed with whole broth and cell lysate of LAB consortium. In liquid broth assay, the cell lysate of LAB consortium astoundingly exhibited up to 85% inhibition of multi-drug resistant Staphylococcus isolates.
Our results suggest antagonistic role of LAB metabolites against methicillin resistant staphylococci.
微生物的多药耐药性是一个严重的问题,无论是在国家层面还是在全球层面。许多研究已经提出了替代抗生素的方法,这些方法的副作用最小或没有。LAB 是人类从古至今已知的最友好的益生菌菌株之一。本研究旨在应对微生物中抗生素耐药性的发展,展示 LAB 联合体对 MDR 临床分离株的抑制活性。
共获得 9 株医院分离的葡萄球菌,根据其发酵甘露醇和与柠檬酸血浆形成凝结的能力,将其分为金黄色葡萄球菌和凝固酶阴性葡萄球菌(CoNS)。所有试验菌均采用 HiMedia(印度)Octadisc Combi 92 进行抗生素敏感性检测。制备了 L.plantarum、L.acidophilus 和 L.casei var. rhamnosus 的组合,并通过琼脂孔扩散法对金黄色葡萄球菌 NCIM 2129 的标准培养物进行了测试。为了确定抑制活性的主要物质来源,从上述组合中制备了全培养液、无细胞上清液和细胞裂解物,并对其进行了测试。首先对标准金黄色葡萄球菌 NCIM 2127 进行了测试,然后对临床分离株进行了测试。
抗生素敏感性谱显示,所有临床分离株均为多药耐药株。三种 LAB 以 1:1:1 的比例组合时,抑制潜力最大。LAB 联合体的全培养液和细胞裂解物表现出最高的拮抗活性。在液体肉汤测定中,LAB 联合体的细胞裂解物惊人地表现出对多药耐药金黄色葡萄球菌分离株高达 85%的抑制作用。
我们的结果表明 LAB 代谢物对耐甲氧西林葡萄球菌具有拮抗作用。